EGFR and neoplasm: Preclinical studies conducted on BRAF-mt mCRC cell lines have shown that BRAF inhibition leads to the rapid feedback activation of EGFR, which could explain the persistence of tumour proliferation despite BRAF inhibition, as shown on Fig. 1b.